Ascendis Pharma A/S (ASND) Faced R&D Setbacks in Q4
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here.
Ascendis Pharma A/S (ASND)
Market is closed
News
- First
- << Previous
- 11 - 20
- Next >>
Ascendis Pharma A/S (NASDAQ:ASND) Q4 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Fourth Quarter 2023 Ascendis Pharma Earnings Conference Call. At this time, all participants are in a listen-only mode.
Ascendis Pharma A/S (NASDAQ:ASND) Q3 2023 Earnings Call Transcript
Operator: Hello, and welcome to Ascendis Pharma Third Quarter 2023 Earnings Conference Call and Webcast.
Here’s What Caused the Volatility in Ascendis Pharma A/S (ASND)
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter investor letter. A copy of the same can be downloaded here.
Ascendis Pharma A/S (NASDAQ:ASND) Q2 2023 Earnings Call Transcript
Operator: Hello, and welcome to Ascendis Pharma Q2 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Here’s Why Ascendis Pharma A/S (ASND) Declined in Q2
Artisan Partners, an investment management company, released its “Artisan Global Discovery Fund” second quarter 2023 investor letter. A copy of the same can be downloaded here.
15 Worst Performing Biotech Stocks in 2023
In this article, we discuss 15 worst performing biotech stocks in 2023.
Here’s Why Baron Health Care Fund Harvested Ascendis Pharma A/S (ASND)
Baron Funds, an investment management company, released its “Baron Health Care Fund” second quarter 2023 investor letter. A copy of the same can be downloaded here.
Ascendis Pharma A/S (NASDAQ:ASND) Q1 2023 Earnings Call Transcript
Operator: Thank you for standing by and welcome to the Q1 2023 Ascendis Pharma Earnings Conference Call. At this time, all participants are in a listen-only mode.
Top 5 Growth Stocks in Biotech
Headquartered in Bermuda, Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) is a biopharmaceutical company focusing on therapeutics for debilitating disorders.
- First
- << Previous
- 11 - 20
- Next >>
Billionaire Hedge Funds
